What Will Happen to AveXis, Inc. (AVXS) Next? The Stock Just Increased A Lot

December 7, 2017 - By Ellis Scott

The stock of AveXis, Inc. (NASDAQ:AVXS) is a huge mover today! The stock increased 7.32% or $6.73 during the last trading session, reaching $98.7. About 449,817 shares traded or 26.32% up from the average. AveXis, Inc. (NASDAQ:AVXS) has risen 95.85% since December 7, 2016 and is uptrending. It has outperformed by 79.15% the S&P500.
The move comes after 8 months positive chart setup for the $3.16B company. It was reported on Dec, 7 by Barchart.com. We have $102.65 PT which if reached, will make NASDAQ:AVXS worth $126.24 million more.

Analysts await AveXis, Inc. (NASDAQ:AVXS) to report earnings on March, 15. They expect $-1.21 EPS, down 31.52 % or $0.29 from last year’s $-0.92 per share. After $-1.52 actual EPS reported by AveXis, Inc. for the previous quarter, Wall Street now forecasts -20.39 % EPS growth.

AveXis, Inc. (NASDAQ:AVXS) Ratings Coverage

Among 4 analysts covering AveXis (NASDAQ:AVXS), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. AveXis had 5 analyst reports since May 13, 2016 according to SRatingsIntel. As per Friday, May 13, the company rating was maintained by Goldman Sachs. The rating was initiated by Wells Fargo with “Market Perform” on Friday, July 15. The stock of AveXis, Inc. (NASDAQ:AVXS) earned “Buy” rating by Bank of America on Friday, October 21. The firm has “Buy” rating given on Friday, August 12 by Jefferies. The stock of AveXis, Inc. (NASDAQ:AVXS) earned “Buy” rating by Jefferies on Monday, September 19.

More notable recent AveXis, Inc. (NASDAQ:AVXS) news were published by: Nasdaq.com which released: “Why AveXis (AVXS) Could Be Positioned for a Slump” on December 06, 2017, also Fool.com with their article: “AveXis Inc.: Buy at the High?” published on July 18, 2017, Reuters.com published: “BRIEF-Avexis Inc CFO Thomas Dee resigns” on October 19, 2017. More interesting news about AveXis, Inc. (NASDAQ:AVXS) were released by: Globenewswire.com and their article: “AveXis Reports Third Quarter 2017 Financial and Operating Results” published on November 09, 2017 as well as Globenewswire.com‘s news article titled: “AveXis Announces Plan to Initiate Pivotal Trial of AVXS-101 in SMA Type 1 …” with publication date: September 29, 2017.

AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company has market cap of $3.16 billion. The Company’s initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. It currently has negative earnings. The firm also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.